Abstract
An extended-release capsule formulation of carbamazepine (Equetro™; Shire, PA, USA) was approved by the US Food and Drug Administration in December 2004 for the treatment of acute manic and mixed episodes associated with bipolar I disorder. Extended-release capsule formulation of carbamazepine offers several advantages to immediate-release carbamazepine formulations such as decreased dosing frequency and lowered plasma carbamazepine fluctuations. These important considerations combine to enhance patient compliance and tolerability, which is essential for the success of any therapeutic treatment regimen. The efficacy, safety, and tolerability of the extended-release capsule formulation of carbamazepine was demonstrated in two randomized, double-blind, placebo-controlled trials and an open-label extension study in patients with bipolar I disorder experiencing either manic or mixed episodes. Although further study is required, the data garnered in these studies, along with the agent’s recent approval by the ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
